Skip to content

Study · Systematic review · 2024

2 results

Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.

Popovic DS, Patoulias D, Popovic LS, Karakasis P, Papanas N, Mantzoros CS

Diabetes research and clinical practice24 Jun 2024Cited by 17 (Europe PMC)

PMID38925294 (opens in a new tab)DOI10.1016/j.diabres.2024.111758 (opens in a new tab)PepBankPUB-38925294
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, a meta-analysis of 9 trials found that tirzepatide did not increase the risk of any cancer.

    In plain wordsIn adults with type 2 diabetes, tirzepatide did not raise the overall cancer risk in short trials, but evidence is preliminary.

    Peptide
    Tirzepatide
    Outcome
    No significant changeRisk of any cancer
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated · 36 to 72 weeksAs given in this study (human).

    Source sentences

    Summary
    tirzepatide does not increase the risk for any cancer (primary outcome)
    2 context sentences
    Summary · context
    We included a total of 9 RCTs with a relatively short study duration, ranging from 36 to 72 weeks.
    Summary · context
    We conducted a meta-analysis of available, up to 1st April 2024, phase 2/3 randomized controlled trials (RCTs) evaluating the use of tirzepatide in T2DM.
  2. 02HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, a meta-analysis of 9 trials found that tirzepatide did not increase the risk of any specific cancer type.

    In plain wordsIn adults with type 2 diabetes, tirzepatide did not raise the risk of specific cancer types in short trials, but evidence is preliminary.

    Peptide
    Tirzepatide
    Outcome
    No significant changeRisk of specific cancer types
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated · 36 to 72 weeksAs given in this study (human).

    Source sentences

    Summary
    or any of the specific cancer types (secondary outcomes)
    2 context sentences
    Summary · context
    We included a total of 9 RCTs with a relatively short study duration, ranging from 36 to 72 weeks.
    Summary · context
    We conducted a meta-analysis of available, up to 1st April 2024, phase 2/3 randomized controlled trials (RCTs) evaluating the use of tirzepatide in T2DM.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.